{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T10:07:32Z","timestamp":1758708452824,"version":"3.41.2"},"reference-count":24,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T00:00:00Z","timestamp":1644883200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Psychiatry"],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>For patients with schizophrenia, clozapine (CLZ) in combination with clonazepam (CLNAZ) is one of the viable therapeutic options. We successfully reduced the doses of CLZ and CLNAZ to the safe range of a polydrug abuse patient. As far as we know, this is the first case of this problem. As there are no relevant guidelines to reduce CLZ or CLNAZ, we hope to share this case to provide a reference for the prevention and treatment of similar patients with multidrug abuse.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>This case report describes a 46-year-old male with a 24-year history of schizophrenia. His main clinical manifestations are auditory hallucinations, persecutory delusion, and emotional instability. In 2012, the patient started taking rifampicin due to tuberculosis and gradually overused CLZ and CLNAZ. Before admission, he took 1,275 mg of CLZ every day and 26 mg of CLNAZ every night. With the help of Therapeutic Drug Monitoring (TDM) and pharmacogenetic testing, we gradually reduced his daily dose of CLZ and CLNAZ and formulated a more reasonable dosing schedule for him. At the time of discharge, the patient took CLZ 450 mg per day and CLNAZ 2 mg per night, with no obvious symptoms of psychosis.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In the process of drug maintenance treatment of schizophrenia, it is necessary to adopt TDM strategy to reduce and treat the abuse of multiple prescription drugs.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fpsyt.2022.831276","type":"journal-article","created":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T04:42:23Z","timestamp":1644900143000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":3,"title":["A Case Report of Excessive Use of Clozapine Combined With Clonazepam"],"prefix":"10.3389","volume":"13","author":[{"given":"Wei","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haifeng","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiang","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zheyi","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuo","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Haihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,15]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"688434","DOI":"10.3389\/fpsyt.2021.688434","article-title":"Prescribing psychotropics: misuse, abuse, dependence, withdrawal and addiction","volume":"12","author":"Chiappini","year":"2021","journal-title":"Front Psychiatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"55","DOI":"10.2174\/157488612800492681","article-title":"Update on the adverse effects of clozapine: focus on myocarditis","volume":"7","author":"De Berardis","year":"2012","journal-title":"Curr Drug Saf."},{"key":"B3","doi-asserted-by":"publisher","first-page":"2","DOI":"10.3390\/brainsci10020105","article-title":"Focus on clozapine withdrawal- and misuse-related cases as reported to the European medicines agency (EMA) pharmacovigilance database","volume":"10","author":"Chiappini","year":"2020","journal-title":"Brain Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.5811\/westjem.2016.10.32322","article-title":"Intentional recreational abuse of quetiapine compared to other second-generation antipsychotics","volume":"18","author":"Klein","year":"2017","journal-title":"Western J Emerg Med."},{"key":"B5","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1038\/s41398-018-0192-9","article-title":"Review of withdrawal catatonia: what does this reveal about clozapine?","volume":"8","author":"Lander","year":"2018","journal-title":"Translat psychiatr."},{"key":"B6","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1002\/phar.1201","article-title":"Neurogenetic disorders and treatment of associated seizures","volume":"33","author":"Faulkner","year":"2013","journal-title":"Pharmacotherapy."},{"key":"B7","doi-asserted-by":"publisher","first-page":"318","DOI":"10.11919\/j.issn.1002-0829.216066","article-title":"Effect of clonazepam co-administered with clozapine on the serum clozapine and norclozapine concentration of patients with schizophrenia: a retrospective survey","volume":"28","author":"Jiang","year":"2016","journal-title":"Shanghai Archiv psychiatr."},{"key":"B8","first-page":"1163","article-title":"Clinical pharmacology of atypical antipsychotics: an update","volume":"13","author":"Mauri","year":"2014","journal-title":"EXCLI J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2165\/00023210-200317050-00002","article-title":"Fatalities associated with therapeutic use and overdose of atypical antipsychotics","volume":"17","author":"Trenton","year":"2003","journal-title":"CNS drugs."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1007\/s00213-019-5179-6","article-title":"The impact of clozapine initiation and cessation on psychiatric hospital admissions and bed days: a mirror image cohort study","volume":"236","author":"Siskind","year":"2019","journal-title":"Psychopharmacology."},{"key":"B11","doi-asserted-by":"crossref","DOI":"10.1097\/JCP.0000000000000179","article-title":"Clozapine-related pericarditis during titration phase in a patient with resistant schizophrenia and concomitant valproate treatment: a case report","volume-title":"J Clin Psychopharmacol.","author":"De Berardis","year":"2014"},{"key":"B12","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1177\/2045125317741449","article-title":"Clozapine discontinuation in early schizophrenia: a retrospective case note review of patients under an early intervention service","volume":"8","author":"Shaker","year":"2018","journal-title":"Therapeutic Adv Psychopharmacol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1055\/s-0043-116492","article-title":"Consensus guidelines for therapeutic drug monitoring in neuropsychopharmacology: update 2017","volume":"51","author":"Hiemke","year":"2018","journal-title":"Pharmacopsychiatry."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1185\/03007995.2012.747952","article-title":"Update on rifampin, rifabutin, and rifapentine drug interactions","volume":"29","author":"Baciewicz","year":"2013","journal-title":"Current Med Res Opinion."},{"key":"B15","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1097\/MAJ.0b013e31814a586a","article-title":"Update on rifampin and rifabutin drug interactions","volume":"335","author":"Baciewicz","year":"2008","journal-title":"Am J Med Sci."},{"key":"B16","doi-asserted-by":"publisher","first-page":"307","DOI":"10.2174\/138920007780655469","article-title":"CYP-mediated clozapine interactions: how predictable are they?","volume":"8","author":"Chetty","year":"2007","journal-title":"Current Drug Metabol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"410","DOI":"10.2174\/138920008784746373","article-title":"Metabolism of atypical antipsychotics: involvement of cytochrome p450 enzymes and relevance for drug-drug interactions","volume":"9","author":"Urichuk","year":"2008","journal-title":"Current Drug Metabol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1097\/00004714-199802000-00015","article-title":"Pharmacokinetic interaction of clozapine and rifampicin in a forensic patient with an atypical mycobacterial infection","volume":"18","author":"Joos","year":"1998","journal-title":"J Clinic Psychopharmacol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.genhosppsych.2007.02.004","article-title":"Clozapine-rifampicin interaction in a patient with pulmonary tuberculosis","volume":"29","author":"Peritogiannis","year":"2007","journal-title":"General Hospit Psychiatr."},{"key":"B20","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1192\/pb.bp.115.051250","article-title":"Prescribing clozapine and rifampicin: clinical impact of their interaction","volume":"40","author":"Parker","year":"2016","journal-title":"BJPsych Bull."},{"article-title":"Clozapine therapy and CYP genotype, In: Medical Genetics Summaries, eds Pratt VM, Scott SA, Pirmohamed M, et al","year":"2012","author":"Dean","key":"B21"},{"key":"B22","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41397-019-0108-y","article-title":"Impact of CYP1A2, CYP2C19, and CYP2D6 genotype- and phenoconversion-predicted enzyme activity on clozapine exposure and symptom severity","volume":"20","author":"Lesche","year":"2020","journal-title":"The Pharmacogenom J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1007\/s00415-011-6235-2","article-title":"Rapid improvement of tardive dyskinesia with tetrabenazine, clonazepam and clozapine combined: a naturalistic long-term follow-up study","volume":"259","author":"Kimiagar","year":"2012","journal-title":"J Neurol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"2050313x19833254","DOI":"10.1177\/2050313X19833254","article-title":"The use of clozapine and clonazepam co-administration in the treatment of a severe tardive dyskinesia: a case report","volume":"7","author":"Haile","year":"2019","journal-title":"SAGE Open Med Case Rep."}],"container-title":["Frontiers in Psychiatry"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.831276\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,15]],"date-time":"2022-02-15T04:42:28Z","timestamp":1644900148000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpsyt.2022.831276\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,15]]},"references-count":24,"alternative-id":["10.3389\/fpsyt.2022.831276"],"URL":"https:\/\/doi.org\/10.3389\/fpsyt.2022.831276","relation":{},"ISSN":["1664-0640"],"issn-type":[{"type":"electronic","value":"1664-0640"}],"subject":[],"published":{"date-parts":[[2022,2,15]]},"article-number":"831276"}}